Artesunate + Artesunate + Sulfadoxine-Pyrimethamine + arthemether + lumefantrine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Malaria
Conditions
Malaria
Trial Timeline
Jul 1, 2005 → Jun 1, 2007
NCT ID
NCT00452907About Artesunate + Artesunate + Sulfadoxine-Pyrimethamine + arthemether + lumefantrine
Artesunate + Artesunate + Sulfadoxine-Pyrimethamine + arthemether + lumefantrine is a approved stage product being developed by Sanofi for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00452907. Target conditions include Malaria.
What happened to similar drugs?
10 of 18 similar drugs in Malaria were approved
Approved (10) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00452907 | Approved | Completed |
Competing Products
20 competing products in Malaria